Winkler, Claudia http://orcid.org/0000-0002-4970-7299
Armenia, Joshua
Jones, Gemma N.
Tobalina, Luis http://orcid.org/0000-0002-1947-8309
Sale, Matthew J.
Petreus, Tudor
Baird, Tarrion
Serra, Violeta
Wang, Anderson T.
Lau, Alan
Garnett, Mathew J.
Jaaks, Patricia
Coker, Elizabeth A.
Pierce, Andrew J.
O’Connor, Mark J.
Leo, Elisabetta http://orcid.org/0000-0002-9761-8637
Funding for this research was provided by:
Claudia Winkler is supported by an AstraZeneca PostDoc Fellowship funding.
EC | European Regional Development Fund (Transcan-2 TH4RESPONS (AC15/00063), Miguel Servet [CP14/00228], FIS [PI17/01080])
Article History
Received: 2 June 2020
Revised: 6 October 2020
Accepted: 11 November 2020
First Online: 18 December 2020
Ethics approval and consent to participate
: All the details on mouse models are described in the paper. All commercially acquired samples were from Champions Oncology. AstraZeneca has a governance framework and processes in place to ensure that commercial sources have appropriate patient consent and ethical approval in place for collection of the samples for research purposes including use by for-profit companies. All work was done under project license 70/8839, 70/8894 and POEC1FFDF granted by the Home Office of the United Kingdom. For the TNBC/ovarian PDX cohort, the ethical review committee of the Vall d’Hebron Institue of Research IRB has approved the use of animals in this study. The animal procol was registered at the Catalan government (FUE-2018-00858322 & ID 6PFJ7JZN5).
: Not applicable.
: All the data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding authors upon reasonable request. Researchers may obtain AZD1775, AZ7648, AZD6738 and AZD0156 with a material transfer agreement from AstraZeneca.
: J.A., G.J.N., L.T., A.L., M.J.O. and E.L. are full-time employees and shareholders of AstraZeneca. M.J.S., T.P., T.B., A.T.W. and A.J.P. were AstraZeneca employees. C.W. is a PostDoc Fellow, and T.P. and M.J.S. were PostDoc Fellows of the AstraZeneca PostDoc program. A patent has been filed to the DDA/WEE1 inhibitor results that can modulate SLFN11 associated chemoresistance presented in the paper.
: We thank AstraZeneca for PostDoc Fellowship funding for this project. V.S. is supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds: Miguel Servet [CP14/00228], FIS [PI17/01080] and Transcan-2 TH4RESPONS (AC15/00063). This work was also supported by the Wellcome Trust Grant 206194.